Retatrutide Before and After: What Preclinical and Early Clinical Research Shows on Body Composition

Retatrutide before-and-after results are more accurately assessed through measurable clinical trial outcomes than through personal photographs or transformation accounts. Researchers evaluate changes in body weight, waist circumference, fat mass, lean mass, and metabolic markers. However, retatrutide results before and after treatment vary by study population, trial duration, dose-escalation schedule, and research protocol.

This article will explore what clinical and preclinical data show about retatrutide-related changes in weight, fat mass, lean body mass, early response, and metabolic health. Qualified professionals who need to buy retatrutide for research purposes can reach Doctor Medica’s staff for sourcing direction.

Key Takeaways

• In the Phase 2 obesity trial, participants lost an average of up to 17.5% of their body weight at 24 weeks and 24.2% at 48 weeks.
• A body-composition substudy involving adults with type 2 diabetes also found significant reductions in total fat mass. The proportion of lean mass lost, however, was similar to that reported with other weight-loss interventions.
• Phase 3 TRIUMPH-1 results reported average weight reductions of up to 28.3% at 80 weeks, with continued reductions in a prespecified extension group through 104 weeks.

About: Doctor Medica is your trusted all-in-one supplier of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like retatrutide. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Doctor Medica, we prioritize serving you better to improve the patient’s quality of life.

What Do Retatrutide Before-and-After Weight Results Show?

The clearest retatrutide before and after data come from controlled clinical trials that track changes in body weight over defined periods. These figures reflect average outcomes across study groups and should not be interpreted as predictions for every participant.

In the Phase 2 obesity trial, adults with obesity or overweight who did not have diabetes received retatrutide or placebo for 48 weeks. By week 24, mean body-weight reductions reached up to 17.5% in the higher-dose groups. At week 48, the largest mean reduction was 24.2%, compared with 2.1% in the placebo group.[1] The additional change between weeks 24 and 48 suggests that the weight response continued to develop rather than reaching an early plateau.

Phase 3 data extended the observation window further. Eli Lilly reported in May 2026 that TRIUMPH-1 participants receiving retatrutide had average weight reductions at 80 weeks of 25.9% in the 4mg group, 28.3% in the 9mg group, and 28.3% in the 12mg group. The corresponding average absolute reduction in the 12mg group was 70.3 pounds. Among participants with a baseline BMI of at least 35 who completed the 80-week study and tolerated therapy, a prespecified extension reported an average reduction of up to 30.3% at 104 weeks in the highest-dose group — this was not the full randomized population. [3]

What Happens in the First Eight Weeks? Early Phase Research Observations

Interest in 8-week retatrutide before-and-after results often comes from the expectation that visible changes should emerge within the first two months. However, current research does not define a standard outcome at eight weeks, as the major clinical trials assessed weight and metabolic changes over longer periods.

Early-phase findings suggest that measurable effects may begin within the first several weeks. In a 12-week Phase 1b study involving adults with type 2 diabetes, the highest-dose group recorded a placebo-adjusted mean weight reduction of up to 8.96 kg. Because the study was small, used gradual dose escalation, and focused primarily on safety, pharmacokinetics, and early pharmacodynamic activity, its findings should be viewed as an initial research signal rather than a typical three-month expectation.[4]

Some participants may notice changes in appetite, eating behavior, or what is informally described as “food noise” before substantial changes in body composition become visible. These experiences are subjective and should not be treated as validated body-composition outcomes. Clinical studies assess appetite, body weight, waist circumference, fat mass, and overall body composition separately, and these measures do not necessarily change at the same rate.

Does Retatrutide Preserve Muscle? Body Composition Beyond Weight Loss

Preserving muscle is an important consideration during weight loss because scale weight reflects more than body fat. It also includes lean tissue, water, and other components, so a large reduction in total weight does not reveal how much came from fat versus lean mass.

A 2025 substudy evaluated body composition in adults with type 2 diabetes enrolled in the Phase 2 retatrutide trial. Using dual-energy X-ray absorptiometry, researchers measured changes in total fat mass and lean mass over 36 weeks. In the higher-dose groups, retatrutide produced significantly greater reductions in fat mass than placebo or dulaglutide.[2]

Lean mass decreased as overall body weight declined. However, the proportion of lean mass loss relative to total weight loss was similar to that observed with other established obesity interventions, and researchers concluded that the greater overall weight reduction did not appear to be accompanied by a disproportionately greater share of lean-mass loss. [2] Lean mass includes more than skeletal muscle, so a reduction measured by body composition scanning should not automatically be interpreted as an equivalent loss of functional muscle. A comprehensive assessment would ideally also include strength and physical performance, dietary protein intake, resistance activity, age, and the pace of weight reduction.

Professionals evaluating body composition changes may also encounter questions about whether retatrutide causes hair loss, a separate concern linked to metabolic or nutritional stress during rapid weight reduction rather than directly to fat or lean mass changes.

What Does Research Show About Fat Loss Specifically?

The body-composition substudy provides more direct information about fat loss than scale weight alone. At 36 weeks, retatrutide was associated with dose-related reductions in total fat mass, with the largest average reductions in higher-dose groups. Reported average percentage changes in total fat mass included approximately 4.9% in the 0.5mg group, 15.2% in the 4mg group, 26.1% in the 8mg group, and 23.2% in the 12mg group — compared with reductions of approximately 4.5% with placebo and 2.6% with dulaglutide. [2] The comparison supports the conclusion that much of the observed weight change was attributable to reduced fat mass rather than lean tissue alone.

TRIUMPH-1 also reported substantial reductions in waist circumference at week 80. Mean decreases were 16.3 cm in the 4 mg group, 21.8 cm in the 9 mg group, and 24.1 cm in the 12 mg group, compared with 3.6 cm in the placebo group. Although waist circumference does not directly measure visceral fat, it remains a useful clinical marker of central adiposity and associated cardiometabolic risk.[3]

Preclinical animal research has also reported reductions in fat mass and body weight with retatrutide. Findings in laboratory animals should not be presented as equivalent to human retatrutide peptide before-and-after outcomes — they are most useful for investigating biological pathways before or alongside clinical research. [5]

Are There Hormonal or Metabolic Changes? What the Research Captures

Retatrutide trials have assessed metabolic changes alongside reductions in body weight. In adults with type 2 diabetes, researchers reported improvements in HbA1c, fasting or daily glucose, and body weight. Phase 3 TRANSCEND-T2D-1 results showed mean HbA1c reductions of up to 2.0% and mean body-weight reductions of up to 16.8% at 40 weeks.[4][6] Lilly’s topline TRIUMPH-1 findings also included improvements in non-HDL cholesterol, triglycerides, systolic blood pressure, high-sensitivity C-reactive protein, and waist circumference.[3]

These findings show that retatrutide’s before-and-after outcomes are not limited to appearance or the number on the scale. However, major published studies have not established a clear retatrutide-specific effect on testosterone. Weight loss and improved metabolic health may affect hormonal status in some populations, but this does not demonstrate that retatrutide directly raises testosterone.

Professionals interpreting these results should consider the population studied, including whether participants had obesity, overweight, or type 2 diabetes, as well as their baseline body weight and BMI, the length of follow-up, and whether findings represent group averages or individual outcomes. Phase 3 reports may also separate results by whether participants remained on treatment, from analyses that include outcomes regardless of adherence, which can produce notably different figures.[3]

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972

[2] Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. doi:10.1016/S2213-8587(25)00092-0

[3] Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Published May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5

[5] Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013

[6] Eli Lilly and Company. Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Published March 19, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant